Comparison of Postoperative Nausea and Vomiting between Remimazolam and propofol in Pati ents Undergoing Oral and Maxillofacial Surgery
Not Applicable
- Conditions
- Symptoms, signs and abnormal clinical and laboratory findings, NEC
- Registration Number
- KCT0006965
- Lead Sponsor
- Pusan National University Dental Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Patients scheduled to undergo oral and maxillofacial surgery
American Society of Anesthesiologist Physical Status (ASA PS) 1, 2
Exclusion Criteria
allergic history(propofol or any benzodiazepine drugs)
poor general condition (American society of Anesthesiology Physical stauts(ASA PS) >3)
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the incidence of postoperative nausea and vomiting
- Secondary Outcome Measures
Name Time Method rescue antiemetics
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Remimazolam's antiemetic effects compared to Propofol in oral surgery patients?
How does Remimazolam's efficacy in reducing PONV compare to Propofol in maxillofacial procedures?
Are specific biomarkers associated with differential response to Remimazolam versus Propofol for PONV prevention?
What adverse event profiles distinguish Remimazolam from Propofol in postoperative oral surgery contexts?
What alternative GABA-A modulators or antiemetic combinations show promise for PONV management in dental surgery?